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http://www.biomedcentral.com/1472-6955/12/19RESEARCH ARTICLE Open AccessThe prevalence of pain at pressure areas and
pressure ulcers in hospitalised patients
Michelle Briggs1*, Michelle Collinson2, Lyn Wilson2, Carly Rivers3, Elizabeth McGinnis4, Carol Dealey5, Julia Brown2,
Susanne Coleman2, Nikki Stubbs6, Rebecca Stevenson2, E Andrea Nelson7 and Jane Nixon2Abstract
Background: Patients with pressure ulcers (PUs) report that pain is their most distressing symptom, but there are
few PU pain prevalence studies. We sought to estimate the prevalence of unattributed pressure area related pain
(UPAR pain) which was defined as pain, soreness or discomfort reported by patients, on an “at risk” or PU skin site,
reported at a patient level.
Methods: We undertook pain prevalence surveys in 2 large UK teaching hospital NHS Trusts (6 hospitals) and a
district general hospital NHS Trust (3 hospitals) during their routine annual PU prevalence audits. The hospitals
provide secondary and tertiary care beds in acute and elective surgery, trauma and orthopaedics, burns, medicine,
elderly medicine, oncology and rehabilitation. Anonymised individual patient data were recorded by the ward
nurse and PU prevalence team. The analysis of this prevalence survey included data summaries; no inferential
statistical testing was planned or undertaken. Percentages were calculated using the total number of patients from
the relevant population as the denominator (i.e. including all patients with missing data for that variable).
Results: A total of 3,397 patients in 9 acute hospitals were included in routine PU prevalence audits and, of these,
2010 (59.2%) patients participated in the pain prevalence study. UPAR pain prevalence was 16.3% (327/2010). 1769
patients had no PUs and of these 223 patients reported UPAR pain, a prevalence of 12.6%. Of the 241 people with
pressure ulcers, 104 patients reported pain, a UPAR pain prevalence of 43.2% (104/241).
Conclusion: One in six people in acute hospitals experience UPAR pain on ‘at risk’ or PU skin sites; one in every 8
people without PUs and, more than 2 out of every five people with PUs. The results provide a clear indication that
all patients should be asked if they have pain at pressure areas even when they do not have a PU.
Keywords: Pain, Pressure ulcers, Risk assessment, PrevalenceBackground
A pressure ulcer (PU) is a “localised injury to the skin
and/or underlying tissue usually over a bony prominence,
as a result of pressure, or pressure in combination with
shear” and they range in severity from skin redness (Cat-
egory 1) and superficial skin loss (Category 2) to severe
ulcers involving fat, muscle and bone (Category 3, 4 or un-
stageable) as defined by the European Pressure Ulcer
Advisory Panel and National Pressure Ulcer Advisory
Panel [1]. These wounds are prevalent, can occur in all
healthcare settings and represent a worldwide challenge,* Correspondence: m.i.briggs@leedsmet.ac.uk
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reproduction in any medium, provided the oras they are associated with high healthcare and personal
costs [2-5].
Pain has been reported by patients to be a major
symptom associated with PUs, with dressing changes be-
ing particularly painful times [6]. PU pain can be debili-
tating, reducing the individual’s ability to participate in
physical and social activities, adopt comfortable posi-
tions, move, walk, and under-go rehabilitation. People
with PU pain describe their experience as “endless pain”
characterised by constant presence, needing to keep still,
equipment and treatment pain [3,7,8]. The desire of
healthcare professionals to understand the extent of this
problem is demonstrated by a number of reviews rele-
vant to the topic of pain and pressure ulcers [5,6,9,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2008, and Pieper et al. 2009 described how PU pain had
been measured in a number of studies [9,10]. They also
synthesised research on the prevalence of PU pain. The
two reviews identify 8 studies reporting the prevalence
of pain associated with pressure ulcers in samples ran-
ging from 20 to 186 participants in diverse populations
including hospital, community and palliative care. In the
two largest studies (>100 participants), pressure ulcer
pain prevalence estimates were 37% and 66%. Data qual-
ity is an issue as only 5 studies, however, used validated
and reliable measures to assess pain. Furthermore, the
methods of pain assessment differed, for example, some
studies described nurse reported pain where nurses are
asked to judge how much pain a patient is experiencing
as opposed to direct patient reported outcomes. The
former has been shown to result in under-reporting of
patients’ pain in other situations [11].
Gorecki et al., (2011) carried out a mixed methods sys-
tematic review [6] and identified and synthesised qualita-
tive and quantitative studies of patients’ reports of PU
pain. Ten studies were included (6 qualitative and 4 quan-
titative) representing the experience of 108 adults with
PUs. The PU pain experience was mapped, producing a
conceptual framework of five domains: communicating
the pain, feeling the pain, impact of pain, self-management
, and professional management. The review concluded
that improved communication of pain was needed be-
tween the individual and health care professionals to pro-
mote more effective PU pain management in the future.
However, the Gorecki et al., (2011) review was limited
because they were unable to evaluate PU descriptors for
Category 1 PUs (the most prevalent PU Category) [6]. A
problem with research in this field is that there is a pau-
city of research about pain associated with Category 1
PUs. Only one patient from the combined review sample
had a Category 1 PU, the majority of patients had mul-
tiple PUs of mixed categories. Furthermore, the system-
atic review of patients’ experiences of pain and pressure
ulceration highlighted that pain at skin sites was experi-
enced by patients prior to PU development but was
often not recognised as important by their health care
professionals [3,6]. Patients felt that they were respon-
sible for communicating pain and that their care pro-
vider was responsible for attending to it, but patients’
views and concerns did not always prompt action and
many healthcare professionals dismissed patients’ re-
ports of pain at pressure areas [6,12].
In order to describe pain in patient populations with
and without PUs, we developed three definitions as
follows:
UPAR pain: Unattributed Pressure Area Related pain
which is defined as pain, soreness or discomfort on any
“at risk” or PU skin site, reported at a patient level.PAR pain: Pressure Area Related pain which is defined
as pain, soreness or discomfort on any “at risk” skin site,
reported at a skin site level (i.e. attributable).
PU pain: Pressure Ulcer pain which is defined as pain,
soreness or discomfort on any PU skin site, reported at a
skin site level (i.e. attributable).
The first in a series, this study sought to estimate the
prevalence of unattributed pressure area related pain
(UPAR pain) in hospital populations in a large represen-
tative sample in order to provide definitive estimates.
This study is part of a suite of 6 studies which comprise
the Pressure UlceR Programme of ReSEarch (PUR-
POSE), funded by the National Institute for Health Re-
search (NIHR PG-0407-10056) which aims to reduce the
impact of PUs on patients through improved risk assess-
ment and the development of measures to capture pa-
tient reported outcomes.Objectives
1. To estimate an overall UPAR pain point prevalence
in an acute hospital population
2. To estimate the point prevalence of UPAR pain in
patients without PUs
3. To estimate the point prevalence of UPAR pain in
patients with PUs.Methods
Study design
We undertook a multi-centre, cross-sectional study in
9 hospitals across 2 large teaching NHS Trusts (6 hos-
pitals) and 1 district general hospital NHS Trust (3
hospitals) in England to establish UPAR pain point
prevalence. Questions about pain were added to the
routine annual PU prevalence audits undertaken in the
participating NHS Trusts. In addition to the standard
PU data recorded by ward and audit teams, patients
were asked two questions relating to pain at pressure
areas by a member of the Tissue Viability Team. These
questions were
1. At any time, do you get pain, soreness or discomfort
at a pressure area (prompt: back, bottom, heels,
elbows or other as appropriate to the patient)
2. Do you think this is related to either; your pressure
ulcer OR lying in bed for a long time OR sitting for
a long time?
The data were asked at a global patient level, and not
by skin site, hence the pressure area related pain is not
attributable to individual skin sites with or without
PUs. These questions were adapted from the case
screening questions used in a large postal survey of pain
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identified day in each Trust during 2009 -2010.
Eligibility criteria
As per standard PU prevalence audit methodology, the
target population was “all inpatients of 18 years of age
or older who were in hospital on the date of the partici-
pating Trust’s PU prevalence audit”. Patients in paediat-
ric, obstetric and psychiatric care settings were excluded
from the pain survey, as the prevalence of PU in these
settings is very low, and hence the data collection to in-
formation burden ratio is unacceptably high in these set-
tings. In addition to the standard PU audit data, the
ward nurse was asked to consider whether each patient
was able to report the presence or absence of pain.
Patients were excluded from the pain prevalence study
where it was considered ethically or clinically inappro-
priate by the ward nurse/clinical team, for example,
those where death was considered to be imminent.
Where patients were assessed as able to report pain
these patients were eligible for inclusion in the pain
prevalence. Where patients were assessed as not able to
report pain this was recorded together with the reasons
for ineligibility.
Data collection
Standard practice for the PU prevalence audit was used
to assess and record data to ensure data capture for the
total hospital population. Anonymised individual patient
data was recorded by a designated ward nurse trained in
the use of the data collection form and skin assessment
as part of the preparation for the audit. Data recorded
included ward speciality, date of birth, gender, height,
weight, ethnicity, mobility, risk assessment scale (as per
local policy) and skin classification by skin site using the
European Pressure Ulcer Advisory Panel classification
[14]. The EPUAP 1998 classification (and not the revised
EPUAP/NPUAP 2009 version) [1] was used as the 1998
version was still in use at the participating sites. The
classification was adapted for audit and research use to
enable confirmation of normal skin and unstageable
PUs. Where a patient had no limb or a chronic wound
these were recorded as N/A and ‘other chronic wound’
respectively for that skin site. The audit forms were
checked by a member of the audit team and where it
was indicated that the patient was well and able to re-
port pain, a member of the Tissue Viability Team asked
the patient the two pain questions.
Analysis
The analysis of this prevalence survey included data
summaries and no inferential statistical testing was
planned or undertaken. Percentages were calculated
using the total number of patients from the relevantpopulation as the denominator (i.e. including all patients
with missing data for that variable). All analyses were
carried out using SAS software.
Ethical approval
The study was approved by the Leeds Central Research
Ethics Committee (REC) prior to data collection. Ref No
09/H1313/14.
Results
Figure 1 describes the flow of participants through each
stage of the process.
Total hospital population
A total of 3,397 patients in 9 acute hospitals were in-
cluded in the routine PU prevalence surveys and this
constitutes our target hospital population. The mean age
of patients was 65.8 (SD 19.23), range 18-103 years. The
numbers of men and women were similar: 48.7% male
(1655/3397), and 50.9% female (1730/3397). The number
of patients audited by place of assessment is presented
in Table 1.
Of the 3,397 participants included in the routine PU
prevalence, 502 (14.8%) patients were reported to have
1066 PUs (mean 2.1 per patient, SD 1.63, range 1-13).
The majority (70.5%; 752/1066) of reported PUs were
Grade 1, 22.2% (237/1066) were Grade 2 and less than 1
in 10 (7.2%; 77/1066) were severe PUs.
Pain prevalence population
Of the 3,397 hospital patients in the PU audit sample,
2010 (59.2%) were considered well enough to respond to
the pain questions and hence were eligible for the pain
prevalence. Of the 2010 patients in the pain prevalence
population, 241/2010 (12.0%) had one or more PU. The
PU profile of the categories observed from the total hos-
pital population and pain prevalence population are de-
tailed in Table 2, illustrating that there were similar
Grades of PU in both populations.
Pain prevalence rates
Of the 2010 people asked the pain questions, 327 said
yes to both questions, indicating they had pain on one
or more skin sites with or without a PU, providing an
overall UPAR pain prevalence of 16.3%. 1769 patients
had no PU and of these 223 patients reported pain, an
UPAR pain prevalence of 12.6%. Of the 241 people with
PUs, 104 patients reported pain at one or more PU site,
an UPAR pain prevalence of 43.2% (104/241).
Discussion
This study is the first to assess UPAR pain in a large
representative hospital population including patients
with and without PUs. The importance of inclusion of
Outline of participant flow
PU prevalence audit:3397
Asked the pain screening 
questions:2010/3397 
(59.2%)
Considered unsuitable for the pain 
screening questions: 1387/3397 (40.8%)
144 (10.4%)   Too unwell
27 (  1.9%)   End of life
20 (  1.4%)   Unconscious
339 (24.4%)   Patient off the ward 
93 (   6.7%)   Isolation / barrier nursing
206 (14.9%)    Patient confused
139 (10.0%)    Communication difficulties
26   (   1.9%)   Other
393 (28.3%)    Reason missing
Patients with pressure-area 
pain:327/2010 (16.3%)Did not provide consent / was ineligible for detailed pain 
assessment:164/327 (50.2%)
7 (  4.3%)   Missed by TVT member
2 (  1.2%)   Transferred to another
healthcare setting
17 (10.4%)   Refused without any
reason
47 (28.7%)   Refused, does not want 
to be involved in
research
39 (23.8%)    Refused, feels poorly or
unwell
14 (  8.5%)   Unable to provide written 
informed consent
1  (  0.6%)     Other
37 (22.6%)    Reason missing
Patients without pressure-
area pain:1683/2010 
(83.7%)
Figure 1 Outline of participant flow.
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12.6% of patients without PUs reported pain on an ‘at
risk’ skin site (one in eight people without obvious tissue
damage). This group could be important because they
are reporting pain over an ‘at risk’ skin site which they
believed to be caused by pressure but they were not yet
displaying damage clinically. There are no other pub-
lished reports of this type of pain.
In light of this finding, there could be gains from im-
proving the recognition and treatment of pain in the ‘at
risk’ population. The relationship between pressure area
related pain and pressure injury is likely to be complex
and this prevalence study was not designed to explainTable 1 Total hospital population by place of assessment
No. of participants %
Medicine 1348 39.7%
Surgery 868 25.6%
Elderly medicine 380 11.2%
Orthopaedic and trauma 305 9.0%
Oncology 211 6.2%
Critical care 179 5.3%
Rehabilitation 79 2.3%
Burns 15 0.4%
Clinical decision units 8 0.2%
Missing 4 0.1%
Total 3397 100%this relationship, rather it provides descriptive data to in-
form further study. As our pain prevalence study was
cross-sectional we are not able to determine whether
pain on an ‘at risk’ skin site is an early indicator of PU
development; a prospective cohort study is currently un-
derway addressing this research question.
In relation to UPAR pain reported by patients with
PUs, 43.2% of patients reported pain. It is important to
note that the pain reported in this study is not necessar-
ily PU pain, since the pain reports were not attributable
to a particular PU, rather any “at risk” or PU skin site ir-
respective of damage. However, the pain prevalence is
more than 3-fold the prevalence found in patients with-
out PUs and the prevalence rate is comparable to the
prevalence of pain in other chronic wounds in European
populations [15,16]. Furthermore, evidence suggests that
the pain management for this group is not comparable
to other painful conditions such as musculoskeletal pain.
For example, in a study of people with PUs, 59% of the
sample reported PU pain but only 2% received analgesia
within 4 hours of the interview [17]. Quirino and col-
leagues in a small study of 20 patients noted that pain
compromised movement and that 80% of patients had
pain for more than 1 hour a day [18]. Fourteen patients
in their study reported use of analgesia (mainly NSAIDS)
but reported little or no effect.
There is a need to improve the assessment and treat-
ment of pain for people with PUs as this will affect
nearly half of the PU population based on our findings.
There is also a need to provide pre-emptive treatment
Table 2 PU prevalence for total and pain prevalence
populations
Grade Total hospital
prevalence
Pain prevalence
population
Total Population 3,397 2010
Number of patients with PU 502 (14.8%) 241 (12.0%)
Total number of PUs 1066 491
Grade of PUs reported
Grade 1 752 (70.5%) 357 (72.7 %)
Grade 2 237 (22.2%) 100 (20.4%)
Grade 3 45 (4.2%) 18 (3.7%)
Grade 4 18 (1.7%) 10 (2.0%)
Unstageable 14 (1.3%) 6 (1.2%)
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ample, in a study which investigated the pain associated
with turning for pressure relief and other nursing proce-
dures, turning was the most painful procedure compared
to tracheal suction, wound drain removal, central line
insertion and femoral sheath removal [19]. It was noted
that despite this painful procedure, patients rarely re-
ceived analgesia prior to turning.
The findings of this study underline the importance of
assessing all patients for the presence/absence of pain
and this should be a fundamental component of pressure
area care. A key recommendation from Gorecki et al.,
2011 was that we need to develop better methods of
communicating about pain in relation to PU develop-
ment [6]. This study adds further information to guide
clinicians and researchers in this regard.
Methodological limitations
Point prevalence rates provide evidence of the scale of a
clinical problem and the general limitations of cross-
sectional studies are acknowledged [4,20-22]. Other limi-
tations of this study are that skin assessment data was
recorded by clinical staff which has inherent limitations
[8,23,24] which may have resulted in over or under-
reporting of PUs or misclassification of Grade or extent
of tissue damage, particularly at Grade 1, which is prone
to misclassification. The pain was recorded at the patient
level and not by skin site and so it was not possible to
assess the level of PU pain. We were not able to record
pain treatment and therefore the quality of pain manage-
ment may differ between wards and could be an add-
itional factor to consider Furthermore, the methodology
used meant that a significant proportion of hospital pa-
tients (40.8%) were not able to participate in the pain
prevalence study due to illness (too unwell, end of life,
unconscious), difficulty in assessing (confused or com-
munication difficulty) or patient unavailable (off the
ward or in isolation). The overall PU prevalence in thehospital population is higher than the pain prevalence
population suggesting that the overall UPAR pain preva-
lence of 16.3% may be an under-estimate and generalis-
ability is limited by our inability to assess really unwell
patients and those with communication difficulties.
Therefore this limits the generalisability to a total hos-
pital population.
Conclusion
The results provide a clear indication for the implemen-
tation of monitoring pressure area related pain, and pain
management in patients with and without PU. This is in
an area which is a priority for patients and impacts upon
the quality of life of nearly half of the population. More
people with PUs reported UPAR pain than those with-
out, however an important minority of patients without
PUs reported UPAR pain. A prospective cohort study is
currently underway to provide further insights into the
relationship between pain and subsequent Category 2
PU development.
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